# The initial care of younger adults with newly diagnosed type 2 diabetes

> **NIH NIH K23** · KAISER FOUNDATION RESEARCH INSTITUTE · 2021 · $193,318

## Abstract

PROJECT SUMMARY
Dr. Anjali Gopalan, MD, MSHP is a board-certified Internist at the Kaiser Permanente Northern California
(KPNC) Oakland Medical Center and a Research Scientist I (equivalent to Assistant Professor) at the KPNC
Division of Research (DOR). With the proposed K23 mentored career development award, Dr. Gopalan will
gain the advanced training and expertise necessary to become an independent investigator who can develop
and implement tailored interventions for patients with early-onset type 2 diabetes (EOT2D). By focusing on
adults with EOT2D, she seeks to address the comparatively poor micro- and macrovascular outcomes in this
population that may result partly from inadequate management of hyperglycemia and other cardiovascular
disease risk factors. Dr. Gopalan’s research premise posits that it is particularly critical for newly diagnosed
patients with EOT2D to achieve early disease control, since tighter glycemic control during the year following
diagnosis confers long-lasting micro- and macrovascular benefits. In support of the premise, the Research
Aims of this K23 are to: 1) use electronic health record [EHR] data to identify EOT2D patient subgroups at
highest risk of inadequate early disease control, 2) identify barriers to and facilitators of initial EOT2D
management, and 3) examine prospective associations between patient-reported factors (e.g., disease-related
distress, health literacy) and inadequate early disease control. The proposed research will be supported by
experienced mentors and advisors, as well as advanced training in the following areas: 1) the use of advanced
statistical modeling, 2) qualitative data analysis to inform intervention development, 3) the role of social
determinants in health, and 4) implementation science. KPNC and DOR are ideal environments for the
proposed work. KPNC is an integrated learning healthcare delivery system with a diverse membership of 4.2
million people (>350,000 with diabetes). DOR has a long track record of effectively training early stage
investigators and has well-established internal research programs and collaborative relationships with nearby
institutions that provide the infrastructure needed for career development. This environment, along with the
proposed Research and Training Plans and an outstanding mentorship team, will enable Dr. Gopalan to
continue to build the skills and generate the foundational data needed to submit an R01-level proposal during
the final years of the proposed award period. In this planned R01, Dr. Gopalan will refine and implement an
intervention (with a design based on the results of the three K23 Research Aims) to improve early care for
newly diagnosed EOT2D patients and evaluate its impact on early outcomes in this growing, high-risk
population. In summary, the proposed K23 award will support the career development of Dr. Gopalan and is
vital to her acquiring the skill set and expertise required to become a successful, independent investigator.

## Key facts

- **NIH application ID:** 10242094
- **Project number:** 5K23DK116968-04
- **Recipient organization:** KAISER FOUNDATION RESEARCH INSTITUTE
- **Principal Investigator:** Anjali Gopalan
- **Activity code:** K23 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $193,318
- **Award type:** 5
- **Project period:** 2018-09-15 → 2023-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10242094

## Citation

> US National Institutes of Health, RePORTER application 10242094, The initial care of younger adults with newly diagnosed type 2 diabetes (5K23DK116968-04). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10242094. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*